Zsa Zsa Weerts

Chapter 7 168 Table S7.4 Other secondary efficacy endpoints (ITT-population). Placebo N =64 Small-intestinal release Peppermint oil N =62 Ileocolonic release Peppermint oil N =63 Measurement Estimated means (SE) Estimated means (SE) Treatment effect (95% CI) P- value Estimated means (SE) Treatment effect (95% CI) P- value Mean worst abdominal pain § Baseline Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 5.50 (0.29) 4.98 (0.29) 4.76 (0.29) 4.68 (0.29) 4.45 (0.29) 4.24 (0.29) 4.39 (0.29) 4.17 (0.29) 4.30 (0.29) 5.64 (0.29) 5.08 (0.29) 4.75 (0.29) 4.53 (0.30) 4.25 (0.30) 3.96 (0.30) 3.99 (0.30) 3.89 (0.30) 3.82 (0.30) - -0.04 (-0.77; 0.68) -0.15 (-0.85; 0.55) -0.30 (-0.98; 0.39) -0.34 (-0.99; 0.32) -0.42 (-1.05; 0.19) -0.54 (-1.13; 0.05) -0.41 (-0.97; 0.14) -0.63 (-1.14; 0.12) - 0.905 0.674 0.394 0.310 0.180 0.074 0.144 0.016 5.54 (0.29) 5.17 (0.29) 4.84 (0.29) 4.64 (0.29) 4.19 (0.29) 4.27 (0.29) 4.17 (0.29) 4.28 (0.29) 3.93 (0.29) - 0.15 (-0.58; 0.87) 0.04 (-0.66; 0.74) -0.08 (-0.76; 0.59) -0.31 (-0.96; 0.35) -0.01 (-0.64; 0.61) -0.25 (-0.85; 0.33) 0.07 (-0.49; 0.63) -0.41 (-0.92; 0.10) - 0.691 0.912 0.808 0.361 0.970 0.391 0.806 0.117 Abdominal discomfort ± Baseline Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 6.35 (0.31) 5.82 (0.31) 5.47 (0.31) 5.39 (0.32) 5.41 (0.32) 5.29 (0.32) 5.25 (0.32) 5.07 (0.32) 4.88 (0.32) 6.43 (0.32) 5.66 (0.33) 5.39 (0.32) 4.98 (0.33) 4.68 (0.33) 4.57 (0.32) 4.38 (0.33) 4.18 (0.33) 4.27 (0.33) - -0.25 (-1.19; 0.69) -0,16 (-1.07; 0.74) -0.49 (-1.39; 0.40) -0.81 (-1.68; 0.05) -0.80 (-1.63; 0.02) -0.95 (-1.74; -0.15) -0.97 (-1.71; -0.24) -0.69 (-1.36; -0.03) - 0.601 0.722 0.282 0.064 0.056 0.020 0.009 0.041 6.53 (0.31) 6.13 (0.32) 5.93 (0.32) 5.74 (0.33) 4.81 (0.33) 4.88 (0.32) 4.92 (0.32) 5.03 (0.33) 4.45 (0.33) - 0.12 (-0.81; 1.06) 0.28 (-0.63; 1.19) 0.16 (-0.74; 1.07) -0.77 (-1.65; 0.10) -0.59 (-1.42; 0.24) -0.50 (-1.30; 0.29) -0.21 (-0.95; 0.53) -0.60 (1.27; 0.06) - 0.795 0.546 0.722 0.083 0.164 0.212 0.572 0.076